ABBV shares edge lower with CCI indicating overbought conditions: weekly report

Traders Union
All News
Financial News
AbbVie slips 1.72% this week

Highlights

AbbVie sustains a bullish medium and long-term trend, trading significantly above dynamic support levels despite recent declines.
Momentum indicators reflect mixed signals, with ongoing buyer dominance but short-term overbought and fatigue conditions suggesting risk of a pullback.
AbbVie is predicted to move sideways in the $242.26 to $245.92 range over the next week, with a breakout above $245.92 required to resume upward momentum.

Regulatory advances and institutional changes shape sentiment this week

AbbVie secured European Commission marketing authorization for Tepkinly in combination with lenalidomide and rituximab to treat follicular lymphoma. The period also saw continued adjustments in institutional holdings and employee participation in global volunteer initiatives.

Mixed weekly momentum as price diverges from overbought signals

On the weekly timeframe, AbbVie trades well above the MA-20, MA-50, and MA-200, reaffirming solid medium- and long-term support, with the MA-50 at $222.03 acting as the closest dynamic floor. Weekly momentum is mixed: the MACD stays bullish, but the ADX at 16.04 shows a weak trend. Weekly RSI at 61.38 suggests ongoing buying interest, while the Stochastic RSI signals neutral momentum with signs of fatigue. CCI and Bull/Bear Power both indicate an overbought market, hinting at the risk of a short-term retracement, while the Awesome Oscillator supports the uptrend. The current price sits at the bottom of the weekly range after steady declines from recent highs, in slight divergence from mixed oscillators.

Sideways consolidation expected as breakout risks remain balanced

For the next 7 trading days, AbbVie is likely to remain range-bound between $242.26 and $245.92, with an even probability of upward or downward movement based on the balance of weekly momentum signals. Price is expected to consolidate near current levels, unless a breakout above $245.92 triggers renewed bullishness. If the price falls below $242.26, additional weakness could follow toward the next dynamic support area. Overall, further sideways consolidation remains the baseline scenario for the coming week.

Jainam Mehta, market strategist, sees AbbVie maintaining its bullish technical structure even as the stock retreated 1.72% during the week. He notes that although long-term momentum remains intact above key moving averages, mixed weekly signals and overbought readings imply a pause or potential retracement. Mehta believes price will likely consolidate within the $242.26 to $245.92 band until a decisive breakout occurs in either direction. "With sentiment stretched and the uptrend intact, I am watching for a range break as a trigger — patience is key for tactical positioning this week."

Previously it was reported that AbbVie’s sustained uptrend was supported by strong technical alignment and positive regulatory developments, though signs of overbought conditions suggested near-term consolidation. The latest price action reinforces this consolidation scenario, with traders advised to monitor a potential breakout above $245.92 for renewed bullish momentum in the week ahead.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.